SEC Form SC 13G filed by Antares Pharma Inc.

$ATRS
Medical/Dental Instruments
Health Care
Get the next $ATRS alert in real time by email
SC 13G 1 tm226438d6_sc13g.htm SC 13G

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 
 

SCHEDULE 13G

 

 
 
Under the Securities Exchange Act of 1934
 
(Amendment No. )*
 

Antares Pharma, Inc.

(Name of Issuer)
 

Common Stock, $0.01 par value per share

(Title of Class of Securities)
 

036642106

(CUSIP Number)
 

December 31, 2021

(Date of event which requires filing of this statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
 
x Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 8 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

 

   

 

CUSIP No. 036642106

 

13G Page 2 of 8 Pages

 

 

1

NAMES OF REPORTING PERSONS

Rubric Capital Management LP

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

State of Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

 

10,800,000 shares of Common Stock

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

 

10,800,000 shares of Common Stock

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

10,800,000 shares of Common Stock

 

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.35%

 

12

TYPE OF REPORTING PERSON

PN, IA

 

         

 

   

 

CUSIP No. 036642106

 

13G Page 3 of 8 Pages

 

 

1

NAMES OF REPORTING PERSONS

David Rosen

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

 

10,800,000 shares of Common Stock

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

 

10,800,000 shares of Common Stock

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

10,800,000 shares of Common Stock

 

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.35%

 

12

TYPE OF REPORTING PERSON

IN

 

         

   

 

CUSIP No. 036642106

 

13G Page 4 of 8 Pages

 

Item 1(a). NAME OF ISSUER:
   
  The name of the issuer is Antares Pharma, Inc. (the "Issuer").

 

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
   
  The Issuer's principal executive offices are located at 100 Princeton South, Suite 300, Ewing, NJ 08628.

 

Item 2(a). NAME OF PERSON FILING:
   
  This statement is filed by:
   
  (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
     
  (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
     
  The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
   
  The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

 

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
   
  The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

 

Item 2(c). CITIZENSHIP:
   
  Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

 

Item 2(d). TITLE OF CLASS OF SECURITIES:
   
  Common stock, $0.01 par value per share (the "Common Stock").

 

Item 2(e). CUSIP NUMBER:
   
  036642106

 

   

 

CUSIP No. 036642106

 

13G Page 5 of 8 Pages

 

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ¨ Broker or dealer registered under Section 15 of the Act,
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
  (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
  (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
  (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
  (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
  (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
  (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
  (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:  _____________________

 

Item 4. OWNERSHIP.
   
 

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

 

The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 170,042,479 shares of Common Stock outstanding as of November 1, 2021, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 4, 2021.

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
  Not applicable.

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
   
  See Item 2. Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

 

   

 

CUSIP No. 036642106

 

13G Page 6 of 8 Pages

 

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
   
  Not applicable.

 

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
   
  Not applicable.

 

Item 9. NOTICE OF DISSOLUTION OF GROUP.
   
  Not applicable.

 

Item 10. CERTIFICATION.

 

  Each of the Reporting Persons hereby makes the following certification:
   
  By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

   

 

CUSIP No. 036642106

 

13G Page 7 of 8 Pages

 

 

SIGNATURES

 

After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

DATED: February 14, 2022

 

RUBRIC CAPITAL MANAGEMENT LP

 

 

By:        /s/ Michael Nachmani      

Name:  Michael Nachmani

Title:    Chief Operating Officer

 

 

/s/ David Rosen     

DAVID ROSEN

 

   

 

CUSIP No. 036642106

 

13G Page 8 of 8 Pages

 

EXHIBIT 1

 

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

 

DATED: February 14, 2022

 

RUBRIC CAPITAL MANAGEMENT LP

 

 

By:        /s/ Michael Nachmani      

Name:  Michael Nachmani

Title:    Chief Operating Officer

 

 

/s/ David Rosen     

DAVID ROSEN

 

   

 

Get the next $ATRS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATRS

DatePrice TargetRatingAnalyst
11/5/2021$5.50 → $5.00Buy
HC Wainwright & Co.
7/16/2021$7.00Buy
Truist Securities
More analyst ratings

$ATRS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

    CHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor.  Dr. Wotton fills the role of Independent Director of the Board, created following Dimension's Series A raise of $15M completed in February 2023. He brings an expert perspective on platform growth opportunities as a leader of multiple global biotechnology and pharmaceutical companies. Dr. Wotton is a serial entrepreneur and inventor with experience spanning scientific research, product development, and transformational busines

    $SGTX
    $VCEL
    $ATRS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medical/Dental Instruments
  • Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

    SAN DIEGO, May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") has expired. On April 26, 2022, Halozyme commenced a tender offer (the "Offer") to purchase all outstanding shares of common stock of Antares (the "Shares") for $5.60 per share in cash, without interest thereon and net of any applicable withholding taxes. As a result of the expiration of the waiting period under the HSR Act, the condition to the Offer relating to the expirat

    $ATRS
    $HALO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

    SAN DIEGO, April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement"). The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May [23], 2022, unless extended in accordance with the terms of

    $ATRS
    $HALO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$ATRS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ATRS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ATRS
SEC Filings

See more

$ATRS
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for TESTOSTERONE UNDECANOATE issued to ANTARES PHARMA INC

    Submission status for ANTARES PHARMA INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    $ATRS
    Medical/Dental Instruments
    Health Care

$ATRS
Leadership Updates

Live Leadership Updates

See more
  • Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources

    EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for Antares' corporate Human Resources ("HR") strategy and development. Claude E. Richardson has more than 25 years of Human Resources leadership experience across multiple industries including pharmaceutical, industrials, financial services and consumer products. His broad-based background in Human Resources includes talent management and acquisition, compensation and benefits, development and training, performance manage

    $ATRS
    Medical/Dental Instruments
    Health Care
  • Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors

    EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device executive with extensive finance and operations experience at publicly traded and private companies. Since 2018, she has served as the Chief Financial Officer of NatureWorks, LLC. Prior to that, she was the Chief Financial Officer at NxThera, Inc. From 2002 to 2012, she also served as the Chief Financial Officer of Tornier, NV, Spine Wave, Inc. and American Medical Systems, I

    $ATRS
    Medical/Dental Instruments
    Health Care
  • Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial

    EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institut

    $ATRS
    Medical/Dental Instruments
    Health Care

$ATRS
Financials

Live finance-specific insights

See more
  • Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

    Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/

    $ATRS
    $HALO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results

    Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which exclu

    $ATRS
    Medical/Dental Instruments
    Health Care
  • Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

    EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The conference ID number is 9589807. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antares

    $ATRS
    Medical/Dental Instruments
    Health Care

$ATRS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more